Idecabtagene vicleucel consists of a CAR T-cell construct targeting B-cell maturation antigen (BCMA) which is expressed on the surface of both normal and malignant plasma cells, promoting survival of myeloma cells. Here, TNFRSF17 is linked to plasma cell myeloma.